Secure your source for quality antibody production. Learn how our experience and flexibility can meet your needs for both small scale and large scale production.
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
March 22-25, 2026 San Diego, CA Booth #1711 Toxicologists and scientists will attend the annual ToxExpo to communicate industry-leading ideas and best practices. With live, semi-li...
April 17-22, 2026 San Diego, CA Booth #4026 The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professiona...
May 11-15, 2026 Boston, MA Booth #1010 Join the American Society of Gene and Cell Therapy to connect with a global community dedicated to advancing genetic and cellular therap...
August 6, 2025 In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the r...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
General Toxicology
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
